查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403523

到 2030 年的综合代谢组测试市场预测：按测试类型、疾病、最终用户和地区进行的全球分析

Comprehensive Metabolic Panel Testing Market Forecasts to 2030 - Global Analysis By Test Type, Disease, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球综合代谢组测试市场规模为 113.2 亿美元，预计在预测期内将以 11.1% 的复合年增长率增长，并在 2030 年达到 236.5 亿美元。

称为综合代谢组 (CMP) 的诊断性血液检查可对一个人的代谢健康状况进行全面评估。它评估与血糖、电解质平衡和器官功能相关的许多标记。 CMP 中通常包括血糖、电解质、肝臟、肾臟和蛋白质水平的测试。此外，该面板可以提供有关肝臟和肾臟等重要器官整体健康状况的深入信息，帮助识别和追踪糖尿病、肝病和肾功能障碍等疾病。很有帮助。

根据国际糖尿病联盟 (IDF) 的数据，全球有超过 5.4 亿人患有糖尿病，到 2045 年，这一数字预计将增加到 7.8 亿以上。

代谢性疾病发生频率增加

推动综合代谢组 (CMP) 检测市场的主要因素之一是糖尿病、肥胖和非酒精性脂肪肝等代谢疾病的全球盛行率不断上升。此外，鑑于与这些疾病相关的生活方式因素和用餐模式越来越普遍，定期代谢分析对于促进早期发现、介入和有效的疾病管理至关重要。

缺乏教育和意识

儘管人们越来越关注预防性医疗保健，但对于完整代谢组测试的重要性仍然存在很大的认识差距。医疗保健专业人员和公众对这些测试提供的全面资料及其在疾病早期检测中的重要性缺乏认识，阻碍了它们的使用。此外，为了克服这项限制，需要针对公众和医疗保健专业人员进行有针对性的教育宣传活动，以促进知识和积极参与代谢健康监测。

标靶治疗与个人化医疗

随着人们越来越重视个人化医疗，市场蕴藏着巨大的机会。随着分子诊断和基因分析的不断进步，将代谢组资料与个人遗传资讯结合可以提高治疗计划的准确性。此外，开发适合每位患者独特代谢特征的标靶治疗将成为可能，这有望提高治疗效果并减少副作用。

价格压力与竞争环境

CMP 测试市场面临巨大的威胁，不仅来自价格压力，还来自产业。由于激烈的竞争，诊断公司之间的价格竞争可能会危及综合代谢组检测服务的长期生存能力。此外，测试机构必须利用成本降低策略、附加价值服务和策略差异化，才能在这个竞争激烈的市场中生存，同时又不牺牲客户满意度。

COVID-19 的影响：

COVID-19 爆发对市场产生了多种影响。常规诊断检测（包括 CMP 检测）出现暂时下降，这最初是由于医疗服务中断、供应链问题以及大流行管理的医疗优先事项变化所造成的。随着医疗保健部门适应新常态，彻底的代谢评估对于确定 COVID-19 对患者（尤其是患有代谢併发症的患者）的影响的重要性越来越受到人们的认识。此外，POC 测试、远端医疗和数位健康解决方案都因疫情而普及，改变了 CMP 测试市场的动态。

预计糖尿病领域在预测期内将是最大的领域。

糖尿病预计将占据最大的市场份额，因为它是一种高度流行的慢性疾病。糖尿病是一种代谢性疾病，影响全世界数百万人，其特征是血糖值升高。此外，糖尿病管理市场提供广泛的产品和服务，包括处方药、血糖监测仪、胰岛素治疗和生活方式改变。由于久坐的生活方式和不良饮食等因素，糖尿病的盛行率不断增加，人们在疾病管理的研发和创新方法方面进行了大量投资。

预计护理中心细分市场在预测期内复合年增长率最高。

市场复合年增长率最高的是即时护理中心领域。由于其易用性、速度以及简化医疗服务的能力，现场护理测试变得越来越受欢迎。现场护理测试的特点是在患者手边或附近位置进行快速诊断和即时结果。这些设施提供广泛的诊断服务，并且可以在几分钟内提供结果。这些服务包括血液检查、尿液检查和其他重要的评估。此外，对分散医疗服务、改善患者就诊和缩短诊断週转时间的日益关注也推动了护理中心的扩张。

占比最大的地区：

CMP测试市场预计将在北美地区占据最大份额。该地区大量的慢性代谢病患者、发达的医疗基础设施以及高度的预防保健意识都构成了该地区的优势。此外，技术开拓、行业巨头的存在、有利的报销做法等正在推动北美 CMP 测试市场的扩张。

复合年增长率最高的地区：

综合代谢组（CMP）测试市场预计将成为亚太地区最高的复合年增长率。许多因素正在推动该地区的成长，包括人口的快速成长、医疗保健意识的提高以及代谢紊乱盛行率的增加。医疗基础设施的改善和尖端诊断技术的引入也推动了亚太地区对全面代谢组测试的需求迅速增长。此外，由于与文明病不断上升以及对早期检测和管理的日益重视，预计该地区的市场将稳定成长。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球综合代谢组测试市场：依测试类型

  • 葡萄糖
  • 钙
  • 电解质
    • 钠
    • 钾
    • 其他电解质
  • 肾功能检查
    • 血中尿素氮（BUN）
    • 肌酸酐
  • 肝功能检查
    • 白蛋白
    • 胆红素
    • 碱性磷酸酶
    • 天门冬胺酸胺基转移酶(AST)
    • 丙氨酸胺基转移酶(ALT)
  • 蛋白质
  • 其他测试类型

第六章全球综合代谢组测试市场：依疾病分类

  • 糖尿病
  • 肾臟疾病
  • 肝病
  • 其他疾病

第七章全球综合代谢组测试市场：依最终用户分类

  • 护理点中心
  • 诊断实验室
  • 医院
  • 其他最终用户

第八章全球综合代谢组测试市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • Charles River Laboratories Inc.
  • Genoptix Inc.
  • Baptist Health Medical Group
  • ARUP Laboratories
  • Scion Lab Services LLC
  • NeoGenomics Laboratories, Inc.
  • Abbott Laboratories
  • Unipath
  • Siemens HealthCare GmbH
  • Nova Medical
  • CENTOGENE NV
  • Quest Diagnostics Incorporated
  • Cleveland HeartLab, Inc.
  • Sonic HealthCare
  • TCG Corp.
  • SYNLAB International GmbH
Product Code: SMRC24748

According to Stratistics MRC, the Global Comprehensive Metabolic Panel Testing Market is accounted for $11.32 billion in 2023 and is expected to reach $23.65 billion by 2030 growing at a CAGR of 11.1% during the forecast period. A diagnostic blood test called a Comprehensive Metabolic Panel (CMP) offers a thorough assessment of a person's metabolic health. It assesses a number of markers linked to blood sugar, electrolyte balance, and organ function. Tests for glucose, electrolytes, and liver, kidney, and protein levels in the blood are commonly included in a CMP. Moreover, this panel helps identify and track diseases like diabetes, liver disease, and kidney dysfunction by providing insightful information about the general health of important organs like the liver and kidneys.

According to International Diabetes Federation (IDF), over 540 million people are suffering from diabetes worldwide, and by 2045 the numbers are expected to cross 780 million marks.

Market Dynamics:

Driver:

Increased frequency of metabolic illnesses

One major factor propelling the market for Comprehensive Metabolic Panel (CMP) testing is the rising prevalence of metabolic disorders worldwide, such as diabetes, obesity, and non-alcoholic fatty liver disease. Additionally, regular metabolic profiling is imperative to facilitate early detection, intervention, and efficient disease management, given the increasing prevalence of lifestyle factors and dietary patterns associated with these conditions.

Restraint:

Low level of education and awareness

Even with the growing focus on preventive healthcare, there is still a significant knowledge gap about the significance of full metabolic panel testing. The lack of awareness among healthcare professionals and the general public regarding the comprehensive range of data these tests offer and their significance in the early identification of illnesses impedes their use. Furthermore, in order to overcome this limitation, focused education campaigns that foster knowledge and proactive participation in metabolic health monitoring are required, aimed at both the general public and healthcare professionals.

Opportunity:

Targeted therapies and personalized medicine

There is a big chance for the market because of the growing emphasis on personalized medicine. The precision of treatment plans can be improved by combining metabolic panel data with individual genetic information as molecular diagnostics and genetic profiling continue to advance. Moreover, this makes it possible to develop targeted therapies that are suited to each patient's particular metabolic profile, enhancing treatment effectiveness and reducing side effects.

Threat:

Pricing pressure and the competitive environment

The CMP testing market is significantly threatened by the industry as well as pricing pressures. A pricing war amongst diagnostic companies could jeopardize the long-term viability of comprehensive metabolic panel testing services due to intense competition. Additionally, laboratories must use cost-cutting strategies, value-added services, and strategic differentiation to survive in this cutthroat market without sacrificing customer satisfaction.

COVID-19 Impact:

There are several ways in which the COVID-19 pandemic has affected the market. A brief drop in routine diagnostic testing, including CMP tests, was initially caused by disruptions in healthcare services, issues with the supply chain, and a change in healthcare priorities toward managing the pandemic. The significance of thorough metabolic assessments in determining the effects of COVID-19 on patients, particularly those with metabolic complications, was acknowledged more as the healthcare sector adjusted to the new normal. Furthermore, point-of-care testing, telemedicine, and digital health solutions have all seen rapid adoption as a result of the pandemic, which has changed the dynamics of the CMP testing market.

The Diabetes segment is expected to be the largest during the forecast period

Due to the fact that diabetes is a chronic condition with a high prevalence, it is expected to hold the largest share of the market. Diabetes is a metabolic disease that affects millions of people worldwide and is typified by elevated blood glucose levels. Moreover, a broad range of goods and services are available in the diabetes management market, such as prescription drugs, glucose monitors, insulin treatments, and lifestyle modifications. Significant investments have been made in research, development, and creative approaches to disease management as a result of the rising prevalence of diabetes, which is fueled by factors like sedentary lifestyles and poor dietary habits.

The Point of care Centers segment is expected to have the highest CAGR during the forecast period

The market's highest CAGR is being seen in the point-of-care centers segment. Point-of-care testing has become increasingly popular because of its ease of use, speed, and capacity to simplify the delivery of healthcare. It is typified by quick diagnostics and real-time results at or close to the patient. These facilities provide a broad range of diagnostic services, with results available in a matter of minutes. These services include blood tests, urinalysis, and other crucial assessments. Additionally, point-of-care center expansion has been driven by the growing emphasis on decentralizing healthcare services, increasing patient accessibility, and shortening diagnosis turnaround times.

Region with largest share:

The market for CMP testing is expected to have the largest share in the North American region. A large patient population with chronic metabolic conditions, a well-established healthcare infrastructure, and a high level of awareness regarding preventive healthcare are some of the factors contributing to the region's dominance. Furthermore, technology developments, the existence of major industry players, and advantageous reimbursement practices have all aided in the expansion of the CMP testing market in North America.

Region with highest CAGR:

The comprehensive metabolic panel (CMP) testing market is expected to grow at the highest CAGR in the Asia-Pacific region. A number of factors are driving the region's growth, such as a quickly growing population, growing healthcare awareness, and an increase in the prevalence of metabolic disorders. The Asia-Pacific region's burgeoning need for comprehensive metabolic panel testing is partly due to improved healthcare infrastructure and the uptake of cutting-edge diagnostic technologies. Moreover, the market in this region is expected to grow at a robust rate due to the increasing prevalence of lifestyle-related diseases and the growing emphasis on early detection and management.

Key players in the market:

Some of the key players in Comprehensive Metabolic Panel Testing market include Charles River Laboratories Inc., Genoptix Inc., Baptist Health Medical Group, ARUP Laboratories, Scion Lab Services LLC, NeoGenomics Laboratories, Inc., Abbott Laboratories, Unipath, Siemens Healthcare GmbH, Nova Medical, CENTOGENE N.V., Quest Diagnostics Incorporated, Cleveland HeartLab, Inc., Sonic Healthcare, TCG Corp. and SYNLAB International GmbH.

Key Developments:

In December 2023, Charles River Laboratories International, Inc. announced an important milestone in their strategic collaboration to manufacture CASGEVY™. CASGEVY is approved in some countries for certain eligible patients. The news follows Charles River's Memphis center of excellence passing back-to-back audits from both the U.S. Food and Drug Administration and the Health Products Regulatory Authority, on behalf of the European Medicines Agency.

In December 2023, Baptist Health Baptist Hospital launched the Inspiration Hall, powered by national leader in hospice and palliative care services, VITAS Healthcare. Located on the first floor near the hospital's imaging center waiting room, the Inspiration Hall is an immersive experience where patients, visitors and hospital team members can submit, read or watch messages of comfort and support that will inspire others in their health journey.

In December 2023, A partnership between ARUP Laboratories and Medicover has made a new companion diagnostic, and thereby a new gene therapy, more accessible to patients in the European Union. ARUP Laboratories, in close collaboration with BioMarin Pharmaceutical Inc., developed AAV5 DetectCDx™, a companion diagnostic that aids in the selection of adult patients with severe hemophilia A who are eligible for treatment with ROCTAVIAN™, a new gene therapy developed by BioMarin.

Test Types Covered:

  • Glucose
  • Calcium
  • Electrolytes
  • Kidney Function Tests
  • Liver Function Tests
  • Proteins
  • Other Test Types

Diseases Covered:

  • Diabetes
  • Kidney Disease
  • Liver Disease
  • Other Diseases

End Users Covered:

  • Point of Care Centers
  • Diagnostic Laboratories
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Comprehensive Metabolic Panel Testing Market, By Test Type

  • 5.1 Introduction
  • 5.2 Glucose
  • 5.3 Calcium
  • 5.4 Electrolytes
    • 5.4.1 Sodium
    • 5.4.2 Potassium
    • 5.4.3 Other Electrolytes
  • 5.5 Kidney Function Tests
    • 5.5.1 Blood Urea Nitrogen (BUN)
    • 5.5.2 Creatinine
  • 5.6 Liver Function Tests
    • 5.6.1 Albumin
    • 5.6.2 Bilirubin
    • 5.6.3 Alkaline Phosphatase
    • 5.6.4 Aspartate Aminotransferase (AST)
    • 5.6.5 Alanine Aminotransferase (ALT)
  • 5.7 Proteins
  • 5.8 Other Test Types

6 Global Comprehensive Metabolic Panel Testing Market, By Disease

  • 6.1 Introduction
  • 6.2 Diabetes
  • 6.3 Kidney Disease
  • 6.4 Liver Disease
  • 6.5 Other Diseases

7 Global Comprehensive Metabolic Panel Testing Market, By End User

  • 7.1 Introduction
  • 7.2 Point of Care Centers
  • 7.3 Diagnostic Laboratories
  • 7.4 Hospitals
  • 7.5 Other End Users

8 Global Comprehensive Metabolic Panel Testing Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Charles River Laboratories Inc.
  • 10.2 Genoptix Inc.
  • 10.3 Baptist Health Medical Group
  • 10.4 ARUP Laboratories
  • 10.5 Scion Lab Services LLC
  • 10.6 NeoGenomics Laboratories, Inc.
  • 10.7 Abbott Laboratories
  • 10.8 Unipath
  • 10.9 Siemens HealthCare GmbH
  • 10.10 Nova Medical
  • 10.11 CENTOGENE N.V.
  • 10.12 Quest Diagnostics Incorporated
  • 10.13 Cleveland HeartLab, Inc.
  • 10.14 Sonic HealthCare
  • 10.15 TCG Corp.
  • 10.16 SYNLAB International GmbH

List of Tables

  • Table 1 Global Comprehensive Metabolic Panel Testing Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Comprehensive Metabolic Panel Testing Market Outlook, By Test Type (2021-2030) ($MN)
  • Table 3 Global Comprehensive Metabolic Panel Testing Market Outlook, By Glucose (2021-2030) ($MN)
  • Table 4 Global Comprehensive Metabolic Panel Testing Market Outlook, By Calcium (2021-2030) ($MN)
  • Table 5 Global Comprehensive Metabolic Panel Testing Market Outlook, By Electrolytes (2021-2030) ($MN)
  • Table 6 Global Comprehensive Metabolic Panel Testing Market Outlook, By Sodium (2021-2030) ($MN)
  • Table 7 Global Comprehensive Metabolic Panel Testing Market Outlook, By Potassium (2021-2030) ($MN)
  • Table 8 Global Comprehensive Metabolic Panel Testing Market Outlook, By Other Electrolytes (2021-2030) ($MN)
  • Table 9 Global Comprehensive Metabolic Panel Testing Market Outlook, By Kidney Function Tests (2021-2030) ($MN)
  • Table 10 Global Comprehensive Metabolic Panel Testing Market Outlook, By Blood Urea Nitrogen (BUN) (2021-2030) ($MN)
  • Table 11 Global Comprehensive Metabolic Panel Testing Market Outlook, By Creatinine (2021-2030) ($MN)
  • Table 12 Global Comprehensive Metabolic Panel Testing Market Outlook, By Liver Function Tests (2021-2030) ($MN)
  • Table 13 Global Comprehensive Metabolic Panel Testing Market Outlook, By Albumin (2021-2030) ($MN)
  • Table 14 Global Comprehensive Metabolic Panel Testing Market Outlook, By Bilirubin (2021-2030) ($MN)
  • Table 15 Global Comprehensive Metabolic Panel Testing Market Outlook, By Alkaline Phosphatase (2021-2030) ($MN)
  • Table 16 Global Comprehensive Metabolic Panel Testing Market Outlook, By Aspartate Aminotransferase (AST) (2021-2030) ($MN)
  • Table 17 Global Comprehensive Metabolic Panel Testing Market Outlook, By Alanine Aminotransferase (ALT) (2021-2030) ($MN)
  • Table 18 Global Comprehensive Metabolic Panel Testing Market Outlook, By Proteins (2021-2030) ($MN)
  • Table 19 Global Comprehensive Metabolic Panel Testing Market Outlook, By Other Test Types (2021-2030) ($MN)
  • Table 20 Global Comprehensive Metabolic Panel Testing Market Outlook, By Disease (2021-2030) ($MN)
  • Table 21 Global Comprehensive Metabolic Panel Testing Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 22 Global Comprehensive Metabolic Panel Testing Market Outlook, By Kidney Disease (2021-2030) ($MN)
  • Table 23 Global Comprehensive Metabolic Panel Testing Market Outlook, By Liver Disease (2021-2030) ($MN)
  • Table 24 Global Comprehensive Metabolic Panel Testing Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 25 Global Comprehensive Metabolic Panel Testing Market Outlook, By End User (2021-2030) ($MN)
  • Table 26 Global Comprehensive Metabolic Panel Testing Market Outlook, By Point of Care Centers (2021-2030) ($MN)
  • Table 27 Global Comprehensive Metabolic Panel Testing Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 28 Global Comprehensive Metabolic Panel Testing Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Comprehensive Metabolic Panel Testing Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.